Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
13
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 13 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Gvoke Hypopen 2-Pack Glucagon | D | $48.3M | +27% | 51,029 | $947 | $1,699.14 |
| Baqsimi Glucagon | D | $21.5M | -16% | 31,463 | $683 | $282.93 |
| Glucagon Emergency Kit Glucagon | D | $19.0M | +3% | 44,158 | $429 | $228.97 |
| Gvoke Hypopen 1-Pack Glucagon | D | $13.4M | +35% | 21,021 | $635 | $1,564.63 |
| Glucagen* Glucagon* · J1610 | B | $4.8M | -18% | 21,431 | $222 | $186.83 |
| Glucagen Glucagon | D | $3.5M | -28% | 6,698 | $526 | $315.61 |
| Gvoke PFS 1-Pack Syringe Glucagon | D | $3.0M | -5% | 4,601 | $641 | $1,568.88 |
| Glucagon Emergency Kit* Glucagon HCL* · J1611 | B | $2.3M | +79% | 17,015 | $138 | $120.43 |
| Glucagon Emergency Kit Glucagon HCl | D | $1.6M | +33% | 3,006 | $540 | $288.54 |
| Gvoke PFS 2-Pack Syringe Glucagon | D | $1.6M | -5% | 1,622 | $982 | $1,531.07 |
| Gvoke Glucagon | D | $964K | +54% | 1,557 | $619 | $1,525.13 |
| Zegalogue Autoinjector Dasiglucagon HCl | D | $184K | +585% | 226 | $813 | $494.77 |
| Zegalogue Syringe Dasiglucagon HCl | D | $8K | n/a | 12 | $698 | $498.55 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.